Recap: Infinity Pharmaceuticals Q3 Earnings

Shares of Infinity Pharmaceuticals INFI were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 20.00% year over year to ($0.16), which were in line with the estimate of ($0.16).

Revenue of $496,000 rose by 44.61% from the same period last year, which beat the estimate of $160,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 09, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/aywrw33f

Technicals

52-week high: $1.68

Company's 52-week low was at $0.60

Price action over last quarter: Up 29.95%

Company Overview

Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development.